Bodle 2023 demonstrated the applicability of the homologous mAb ELISA as a replacement for the SRID assay for HA antigen quantitation and stability assessment.
Narayan 2023 developed a Surface Plasmon Resonance-based method using influenza subtype or lineage HA-specific mAbs to measure the HA concentration in multivalent influenza vaccines, which eliminates the need for annually produced antisera reagents.
Qian 2023 developed a streamlined subtype-specific, reference antigen and antisera-free method (CombE-IDMS) for rapidly assaying the potency of influenza vaccines as an alternate to the SRID assay.
Cheung 2022 developed two ELISA-based potency assays for group 1 influenza A viruses using cross-reactive nanobodies.